Episode

Vaccine aspiration requirement confirmed, why is this not happening

Podcast
Dr. John Campbell
Published
Sep 17, 2026
Duration seconds
1482
Processing state
not_requested
Canonical source
https://traffic.megaphone.fm/VG7869267517.mp3
Audio
https://traffic.megaphone.fm/VG7869267517.mp3
JSON
/v1/public/podcasts/dr-john-campbell-7851784/episodes/vaccine-aspiration-requirement-confirmed-why-is-this-not-happening
Markdown
/podcast/dr-john-campbell-7851784/vaccine-aspiration-requirement-confirmed-why-is-this-not-happening.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/dr-john-campbell-7851784/episodes/vaccine-aspiration-requirement-confirmed-why-is-this-not-happening/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/dr-john-campbell-7851784/vaccine-aspiration-requirement-confirmed-why-is-this-not-happening.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Oxford vaccine and blood clots https://www.dailymail.co.uk/news/article-10266585/AstraZeneca-uncovers-trigger-blood-clots-jab.html https://www.gov.uk/government/publications/covid-19-vaccination-blood-clotting-information-for-healthcare-professionals/information-for-healthcare-professionals-on-blood-clotting-following-covid-19-vaccination From 4 January to 4 August AZ vaccine administered across the UK 24.8 million first doses 23.9 million second doses 412 suspected cases of CVST (Cerebral Sinus Vein Thrombosis) have been reported across the UK (Only 43 suspected cases were after the second dose of AZ vaccine) Overall incidence of CVST After first dose, 14.9 per million After second dose, 1.8 per million CVST is a complication of COVID-19 infection 42.8 per million MHRA as of 11 August, there were 73 fatal cases from the 411 events ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome https://www.science.org/doi/10.1126/sciadv.abl8213 Vaccines derived from chimpanzee adenovirus As part of the largest vaccination campaign in history, Ultra rare side effects not seen in phase 3 trials, including thrombosis with thrombocytopenia syndrome (TTS) Adenoviruses deployed as vaccination vectors versus SARS-CoV-2 bind to platelet factor 4 (PF4), a protein implicated in the pathogenesis of HIT. heparin-induced thrombocytopenia Computational simulations to demonstrate an electrostatic interaction mechanism with PF4, which was confirmed experimentally by surface plasmon resonance. These data confirm that PF4 is capable of forming stable complexes with clinically relevant adenoviruses, an important step in unravelling the mechanisms underlying TTS. Platelet factor 4 (PF4) https://en.wikipedia.org/wiki/Platelet_factor_4 https://www.nature.c…